Fibrostenosis Focused Therapeutics - RFP
Funds research-based development of innovative non-surgical therapies for fibrotic complications in IBD, focusing on clinically informed, multidisciplinary approaches.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (Letter of Intent) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; renewals possible if milestones are met.
Summary: Supports development of non-surgical therapies for fibrotic complications in IBD, emphasizing multidisciplinary and clinically informed approaches.
Key Information: Preproposal submission required before LOI and full proposal; indirect costs capped at 10%.
Description
This opportunity funds research-based product development for non-surgical therapies targeting fibrosis (fibrostenosis) in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The initiative seeks to accelerate the discovery and advancement of innovative therapeutics—such as small molecules, biologics, gene/cell therapies, or differentiated devices—that address fibrotic complications in IBD patients, especially strictures, with a clear clinical rationale and evidence in human IBD. The program encourages multidisciplinary collaborations and projects that originate from clinical observations or published human data.
